[Diabetic nephropathy and ACE inhibitors]

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Type 2 diabetes and diabetic nephropathy significantly reduce life expectancy, with cardiovascular disease as the primary cause of death.
• A majority of patients requiring renal replacement therapy have type 2 diabetes.
• Inhibition of the renin-aldosterone-angiotensin system offers benefits in managing diabetes mellitus, including reducing nephropathy incidence and progression.

Purpose of the Study:

• To compare the efficacy of ACE inhibitors and ARBs in treating diabetic nephropathy in type 2 diabetes.
• To evaluate the impact of these therapies on mortality and disease progression.
• To establish a first-choice therapy recommendation based on current evidence and economic factors.

Main Methods:

• Review of large-scale studies and meta-analyses published within the last 15 years.
• Analysis of data concerning mortality reduction and nephropathy progression.
• Consideration of economic factors in therapeutic recommendations.

Main Results:

• ACE inhibitors demonstrated a significant reduction in mortality (approximately 20%) for type 2 diabetic nephropathy.
• Angiotensin-receptor blockers (ARBs) have not yet shown a documented effect on mortality but do slow nephropathy progression.
• ACE inhibitors are the established standard for type 1 diabetic nephropathy, with growing evidence for their superiority in type 2.

Conclusions:

• ACE inhibitors should be considered the first-line therapy for diabetic nephropathy in patients with type 2 diabetes mellitus.
• The established mortality benefit and economic advantages support the use of ACE inhibitors.
• While ARBs show promise in slowing progression, ACE inhibitors offer a more comprehensive benefit profile currently.